These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 21725613

  • 21. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y.
    PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
    [Abstract] [Full Text] [Related]

  • 22. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.
    Baumann P, Schneider L, Mandl-Weber S, Oduncu F, Schmidmaier R.
    Anticancer Drugs; 2012 Jan; 23(1):131-8. PubMed ID: 21959532
    [Abstract] [Full Text] [Related]

  • 23. Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary.
    Kudoh A, Oishi T, Itamochi H, Sato S, Naniwa J, Sato S, Shimada M, Kigawa J, Harada T.
    Int J Gynecol Cancer; 2014 Mar; 24(3):444-53. PubMed ID: 24552895
    [Abstract] [Full Text] [Related]

  • 24. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P, Li C, Zheng Y, Peng Q, Xiao H, Huang Y, Zhu X.
    Drug Des Devel Ther; 2017 Mar; 11():1115-1126. PubMed ID: 28435223
    [Abstract] [Full Text] [Related]

  • 25. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
    Zhu YR, Min H, Fang JF, Zhou F, Deng XW, Zhang YQ.
    Cancer Biol Ther; 2015 Mar; 16(4):602-9. PubMed ID: 25869769
    [Abstract] [Full Text] [Related]

  • 26. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
    Chang KY, Tsai SY, Wu CM, Yen CJ, Chuang BF, Chang JY.
    Clin Cancer Res; 2011 Nov 15; 17(22):7116-26. PubMed ID: 21976531
    [Abstract] [Full Text] [Related]

  • 27. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W.
    Biochem Pharmacol; 2012 May 01; 83(9):1146-58. PubMed ID: 22285225
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R, Angulo P, Chen C, Creasy KT, Spear BT, Hundley J, Daily MF, Shah M, Evers BM.
    Anticancer Res; 2012 Jul 01; 32(7):2531-6. PubMed ID: 22753710
    [Abstract] [Full Text] [Related]

  • 32. Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model.
    Matsushima M, Kikuchi E, Matsumoto K, Hattori S, Takeda T, Kosaka T, Miyajima A, Oya M.
    Int J Oncol; 2015 Jul 01; 47(1):377-83. PubMed ID: 25963317
    [Abstract] [Full Text] [Related]

  • 33. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.
    Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin J, Feng GK, Zhu XF.
    PLoS One; 2013 Jul 01; 8(3):e59879. PubMed ID: 23533654
    [Abstract] [Full Text] [Related]

  • 34. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
    Kim A, Lee JE, Lee SS, Kim C, Lee SJ, Jang WS, Park S.
    Int J Cancer; 2013 Aug 15; 133(4):984-96. PubMed ID: 23475782
    [Abstract] [Full Text] [Related]

  • 35. Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma.
    Hugle M, Fulda S.
    Cancer Lett; 2015 Apr 28; 360(1):1-9. PubMed ID: 25637161
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
    Brünner-Kubath C, Shabbir W, Saferding V, Wagner R, Singer CF, Valent P, Berger W, Marian B, Zielinski CC, Grusch M, Grunt TW.
    Breast Cancer Res Treat; 2011 Sep 28; 129(2):387-400. PubMed ID: 21046231
    [Abstract] [Full Text] [Related]

  • 38. The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy.
    Hernlund E, Olofsson MH, Fayad W, Fryknäs M, Lesiak-Mieczkowska K, Zhang X, Brnjic S, Schmidt V, D'Arcy P, Sjöblom T, De Milito A, Larsson R, Linder S.
    Eur J Cancer; 2012 Feb 28; 48(3):396-406. PubMed ID: 22154651
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis.
    Evert M, Calvisi DF, Evert K, De Murtas V, Gasparetti G, Mattu S, Destefanis G, Ladu S, Zimmermann A, Delogu S, Thiel S, Thiele A, Ribback S, Dombrowski F.
    Hepatology; 2012 May 28; 55(5):1473-84. PubMed ID: 22271091
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.